Evolus, INC Form 4 insider transactions

Evolus officer Rui Avelar sold 3,119 shares of common stock to cover tax withholding obligations related to restricted stock unit awards.

Evolus, Inc. CEO David Moatazedi sold 13,669 shares of common stock to cover tax withholding obligations related to restricted stock unit awards.

Evolus, Inc. CEO David Moatazedi reported the vesting of performance-based restricted stock units and a subsequent sale of shares to cover tax obligations.

Evolus Chief Medical Officer Rui Avelar sold shares to cover tax obligations following the vesting of performance restricted stock units.

Evolus, Inc. Director Karah Parschauer was granted 45,559 restricted stock units, vesting on February 17, 2027.

Evolus, Inc. Director Brady Stewart was granted 45,559 restricted stock units, which will vest in February 2027.

Evolus, Inc. Chief Financial Officer Tatjana Mitchell received grants of restricted stock units, performance stock units, and stock options.

Evolus, Inc. Director Albert G. White III was granted 45,559 restricted stock units, vesting on February 17, 2027.

Evolus, Inc. CEO David Moatazedi received substantial grants of restricted stock units, performance stock units, and stock options, aligning his compensation with future company performance.

Evolus, Inc. Director Vikram Malik received a grant of 45,559 Restricted Stock Units, increasing his beneficial ownership to 321,109 shares.

Evolus' Chief Medical Officer and Head of R&D, Rui Avelar, received significant equity awards including restricted stock units, performance stock units, and stock options, signaling long-term incentive alignment.

Evolus, Inc. Director David N. Gill was granted 45,559 restricted stock units, which will vest on February 17, 2027.

Evolus, Inc. CEO David Moatazedi sold 10,539 shares of common stock for $7.1507 per share to cover tax withholding obligations.

Evolus, Inc.'s Chief Medical Officer, Rui Avelar, sold 2,261 shares of common stock on December 22, 2025, to cover tax withholding obligations related to restricted stock unit vesting.

Evolus, Inc. Chief Financial Officer Tatjana Mitchell received grants of restricted stock units and stock options.

Evolus' Chief Marketing Officer, Tomoko Yamagishi-Dressler, sold 5,722 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Evolus, Inc. Director Brady Stewart acquired 30,000 shares of common stock at a weighted average price of $6.8162.

Evolus, Inc. CEO and Director David Moatazedi reported the sale of 127,905 shares of common stock across two transactions in mid-June 2025.

Evolus, Inc. Director Albert G. White III has acquired 20,000 shares of common stock at a weighted average price of $9.45, increasing his direct beneficial ownership to 50,378 shares.

Rui Avelar, Chief Medical Officer & Head of Research and Development at Evolus, Inc., sold 3,385 shares of common stock on May 12, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Evolus CFO Sandra Beaver sold 6,494 shares of common stock on May 13, 2025, to cover tax withholding obligations related to vesting restricted stock units.

David Moatazedi, a director and officer of Evolus Inc., sold shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Evolus, Inc. CEO David Moatazedi sold 6,251 shares of common stock on March 27, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Evolus, Inc. officer Rui Avelar sold 27,904 shares of common stock on March 18, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Evolus CFO Sandra Beaver sold 8,996 shares of common stock on March 18, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Tomoko Yamagishi-Dressler, Chief Marketing Officer of Evolus Inc., sold 4,536 shares of common stock on March 18, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Director David Moatazedi sold 103,376 shares of Evolus, Inc. to cover tax withholding obligations related to vesting restricted stock units.

Director Karah Parschauer sold 12,888 shares of Evolus, Inc. (EOLS) common stock at an average price of $12.9939 on March 12, 2025.

Chief Marketing Officer of Evolus, Inc., Tomoko Yamagishi-Dressler, reports acquisition of stock and option awards.

Sandra Beaver, CFO of Evolus, Inc., reports the acquisition of common stock, performance restricted stock units, and stock options.